Data gathered: March 12
AI Stock Analysis - Caribou Biosciences (CRBU)
Analysis generated December 9, 2024. Powered by Chat GPT.
Caribou Biosciences is a biotechnology firm specializing in genome editing technology. Leveraging CRISPR technology, the company aims to develop transformative therapeutic solutions. Caribou focuses on cutting-edge science to create treatments for serious diseases, which places it in a high-risk, high-reward bracket of the biotech industry.
Stock Alerts - Caribou Biosciences (CRBU)
 |
Caribou Biosciences | March 11 Price is down by -5.4% in the last 24h. |
|
Caribou Biosciences | March 10 Price is down by -5.2% in the last 24h. |
|
Caribou Biosciences | March 4 Price is up by 5.6% in the last 24h. |
|
Caribou Biosciences | March 3 Price is down by -6% in the last 24h. |
Alternative Data for Caribou Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 17 | Sign up | Sign up | Sign up |
| Patents | 45 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,408 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,523 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 174 | Sign up | Sign up | Sign up |
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
| Price | $1.04 |
| Target Price | Sign up |
| Volume | 163,090 |
| Market Cap | $106M |
| Year Range | $1.04 - $2.79 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Medical Devices |
In the news
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 10 - GlobeNewswire |
|
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMarch 6 - GlobeNewswire |
|
Caribou Biosciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; February 24, 2025 Deadline to file Lead Plaintiff MotionFebruary 24 - GlobeNewswire |
|
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud LawsuitFebruary 24 - Finnhub |
|
Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBUFebruary 23 - Finnhub |
|
February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBUFebruary 20 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2M | 10M | -8.4M | -35M | -38M | -0.382 |
| Q2 '24 | 3.5M | 11M | -8M | -38M | -43M | -0.436 |
| Q1 '24 | 2.4M | 15M | -12M | -41M | -45M | -0.460 |
| Q4 '23 | 19M | 9.7M | 9.1M | -35M | -37M | -0.390 |
| Q3 '23 | 24M | 9.7M | 14M | -10M | -15M | -0.120 |
Insider Transactions View All
| MCCLUNG BARBARA G filed to sell 443,502 shares at $1.4. February 21 '25 |
| Kanner Steven filed to sell 431,556 shares at $1.4. February 21 '25 |
| Khan Ruhi Ahmad filed to sell 66,936 shares at $1.4. February 21 '25 |
| Ryali Sriram filed to buy 17,360 shares at $1.4. January 30 '25 |
| Rizvi Syed Ali-aamir filed to sell 59,373 shares at $6.3. January 20 '23 |
Similar companies
Read more about Caribou Biosciences (CRBU) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Caribou Biosciences?
The Market Cap of Caribou Biosciences is $106M.
What is the current stock price of Caribou Biosciences?
Currently, the price of one share of Caribou Biosciences stock is $1.04.
How can I analyze the CRBU stock price chart for investment decisions?
The CRBU stock price chart above provides a comprehensive visual representation of Caribou Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Caribou Biosciences shares. Our platform offers an up-to-date CRBU stock price chart, along with technical data analysis and alternative data insights.
Does CRBU offer dividends to its shareholders?
As of our latest update, Caribou Biosciences (CRBU) does not offer dividends to its shareholders. Investors interested in Caribou Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Caribou Biosciences?
Some of the similar stocks of Caribou Biosciences are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.